Interviews with and commentary from experts and innovators in hematology.
ASH Annual Meeting
Is Rivaroxaban Safe as Long-Term Prevention for Deep-Vein Thrombosis?
Multiple Advances in Multiple Myeloma
What Was Hot at ASH 2015?
Rivaroxaban in Cancer-Associated VTE: Results from CALLISTO
Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL
The Balancing Act of Caring for Older Patients with Hemophilia
Ibrutinib Beats Temsirolimus in Relapsed/Refractory MCL
Improving Quality of VTE Care
The PROs of Patient-Reported Outcomes
Induction Chemotherapy for AML: Understanding the Patient Experience
Late-Breaking Abstract: First-in-Man Trial of CAR T Cells in Myeloma
Ixazomib Extends PFS in the TOURMALINE-MM1 Trial
Evolving Issues in Anticoagulation
Predicting Prognosis in Myelodysplastic Syndromes
New Approaches in CLL and Prolymphocytic Leukemia
Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic Anemia
Optimizing Therapy in Sickle Cell Disease
Controversy over Quality
Eligibility Criteria Not Associated with Adverse Events in RCTs
Newly Approved Drugs: How Should We Use Them in the Clinic?
Guiding Hematologic Care with Genetic Testing
ASH Meeting on Hematologic Malignancies
Brad Schenkel, MSc: Predicting Hospitalizations, ER Visits Among CLL Patients
Jaleh Fallah, MD: Is the Combo of Abbreviated Chemo Plus Radiation Therapy a Viable Option for DLBCL Patients?
Asher Alban Chanan-Khan, MD: Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL
Ksenia Romanova, MD: Age, Sex, Timing of Treatment Predict Avascular Necroses in Children with ALL
Collaborative Care Delivery Reduces Travel Burden for AML Patients
Highlights of the 2015 ASH Meeting on Hematologic Malignancies
HIV-Associated Lymphoma: Treatment Patterns and Survival in the Antiretroviral Era
The Future of Clinical and Translational Research in Hematologic Malignancies
Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients
ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients
SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients
Ruxolitinib in CMML: Study Shows Promising Results
Options for Treating the High-Risk APL Patient
PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape